EP Patent

EP2266968A3 — Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors

Assigned to Genzyme Corp · Expires 2011-05-18 · 15y expired

What this patent protects

Disclosed is a novel enantiomeric synthesis of ceramide-like inhibitors of UDP-glucose: N -acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.

USPTO Abstract

Disclosed is a novel enantiomeric synthesis of ceramide-like inhibitors of UDP-glucose: N -acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.

Drugs covered by this patent

Patent Metadata

Patent number
EP2266968A3
Jurisdiction
EP
Classification
—
Expires
2011-05-18
Drug substance claim
No
Drug product claim
No
Assignee
Genzyme Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.